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26 Abstract
27
28 Background. Triple negative breast cancer (TNBC) is aggressive and treatment resistant. 
29 Evidence suggests that deficits in melatonin signaling increase TNBC risk: conditions that 
30 suppress melatonin increased incidence, low melatonin receptor expression correlates with 
31 worse prognosis, and high-dose melatonin can inhibit TNBC. Together this suggests that 
32 normalizing pineal melatonin could reduce TNBC incidence and/or mortality. The goal of this 
33 study was to determine whether small physiological deficits in melatonin alone, can increase 
34 risk for TNBC, and how ‘normal’ melatonin would be protective.
35 Methods. The effect of melatonin treatment on 4t1 cells in vitro was measured using the MTT 
36 cell viability assay, and gene expression of breast cancer and melatonin signaling markers. The 
37 effect of pineal gland status on 4t1 cell allografts was tested in C3Sn mice (Mus Musculus) with 
38 either an intact pineal (control) or surgical removal of the pineal causing a ~50% deficit in 
39 plasma melatonin. Orthotopic tumors were assessed by histopathology and metastasis by strain 
40 specific qPCR against 4t1 cell and host gDNA.
41 Results. Melatonin treatment induced significant changes in gene expression, with a significant 
42 reduction in derived PAM50 Risk of Recurrence score (ROR in Not treated = 65.5 ± 10.6 Mean 
43 SEM; Treated with 25pg/ml of melatonin 20.8 ± 8.3; P = 0.008), suggesting melatonin treatment 
44 would improve prognosis. A ~50% reduction in plasma melatonin increased orthotopic tumors, 
45 but this was non-significant, and had no effect on metastasis from tail vein allograft.
46 Conclusions. Physiological deficits in melatonin do alter the oncogenic status of 4t1 tumor cells 
47 but this has only a limited effect on growth and metastasis in vivo. Lack of significance in 
48 orthotopic tumor formation may be due to small sample size, and it is possible that any 
49 protective effect of melatonin occurs earlier in tumor development than we have tested. 
50  
51
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52 Introduction
53
54 Breast cancer is a leading cause of death among women in industrialized countries, with 
55 ~250,000 new cases and ~40,000 deaths each year in the United States [1]. The etiology of 
56 breast cancer is multifactorial and can result in a spectrum of presentations that have divergent 
57 prognoses. Notably, hormone receptor deficient breast cancers are typically aggressive and 
58 treatment resistant, with triple negative breast cancer (TNBC) accounting for 12-17% of cases, 
59 but having a higher proportion of total mortality [2].
60
61 Because TNBC is often treatment resistant and life-threatening, factors that affect incidence 
62 and/or severity can therefore be effective in limiting cancer morbidity and mortality [3]. One 
63 surprising risk factor for breast cancer is exposure to artificial light-at-night (ALAN). ALAN 
64 correlates with increased breast cancer incidence, and night shift work that would expose 
65 individuals to ALAN correlates with a marked increase in estrogen receptor negative breast 
66 cancer [4–7]. Consistent with this correlation, a reduced response to light in blind women has a 
67 protective effect against breast cancer [8,9]. 
68
69 Light acts on multiple aspects of physiology and behavior and the mediating mechanisms of 
70 these effects may be complex [10]. Current evidence does suggest that the suppression of 
71 pineal melatonin by light is a major contributor to these effects [11]. Pineal melatonin is 
72 suppressed by light at night in a dose dependent manner [12,13]. Additionally, melatonin 
73 receptors are expressed in breast tissue and MT1 melatonin receptor expression correlates with 
74 positive outcomes in breast cancer [14–16]. Finally, high dose exogenous melatonin inhibits 
75 mammary cell division in vitro, and mammary tumor growth in vivo [17–20].
76
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77 Although most research points to an anti-estrogenic protective effect of melatonin, in patients 
78 with TNBC, melatonin receptor expression does correlate with survival, and polymorphisms of 
79 melatonin signaling correlate with incidence [16,21]. Further, an effect of melatonin on TNBC 
80 cells is also supported experimentally. In vitro, melatonin has an oncostatic effect on TNBC cell 
81 invasiveness and proliferation [22,23]. In vivo, extremely high doses of exogenous melatonin 
82 inhibit TNBC xenograft growth, and have oncostatic effects on tumor microenvironment, 
83 especially immune and angiogenic markers [24,25]. 
84
85 Based on this evidence, we might hypothesize that maintaining optimal plasma melatonin levels 
86 would reduce the burden of TNBC [11,16]. However, these studies do not show whether 
87 physiological deficits in endogenous melatonin levels, such as would occur with exposure to 
88 ALAN, are sufficient to increase risk for hormone receptor deficient breast cancer. Nor do they 
89 adequately demonstrate which stages in neoplastic development are affected by melatonin: 
90 initiation, promotion, progression and/or metastasis [26]. 
91
92 The goal of this study was to determine whether physiologically realistic deficits in endogenous 
93 melatonin impact the behavior of a hormone receptor deficient breast cancer, using the mouse 
94 4t1 TNBC cell line [27–29]. We first assessed effects of melatonin in vitro on cell viability and 
95 then on expression of genes that give a prognostic prediction and assess potential mechanisms 
96 of melatonin action [30,31]. We then tested the effects of pineal melatonin on 4t1 cells in vivo. 
97 Pineal melatonin competent C3Sn mice were sham operated (Intact-control), or had the pineal 
98 gland tip surgically removed (PinealX) to generate a model of ~50% melatonin deficiency 
99 [12,32–34]. First, an orthotopic 4t1 cell allograft was used to assess the effect of pineal 
100 melatonin on viability and formation of solid tumors [35]. Second, a tail-vein 4t1 cell allograft was 
101 used to assess the effect of pineal melatonin on metastasis [36].
102
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103 Materials and methods
104
105 Cells. 4t1 cells are a mouse mammary tumor cell line with features of TNBC: low Esr1, absent 
106 Pgr, and normal or low Errb2/Her2 [28,29]. Cells were sourced commercially (ATCC, Manassas, 
107 VA), and grown in Roswell Park Memorial Institute medium (RPMI; ATCC, Manassas, VA), with 
108 10% fetal bovine serum (FBS; MidSci, Valley Park, MO) and 1% penicillin/streptomycin 
109 (Pen/Strep; HyClone, Logan, UT). There was a maximum of five passages before experimental 
110 use.
111
112 Animals. Animal care and use was conducted in accordance with U.S. Public Health Service 
113 Policy on Humane Care and Use of Laboratory Animals and approved by the New Mexico Tech 
114 Institutional Animal Care and Use Committee. C3Sn.BLiA-Pde6b+/DnJ (C3Sn) mice were 
115 selected for use in this study because they produce pineal melatonin, are highly susceptible to 
116 breast cancer, and do not suffer from retinal degeneration like the background C3H/He mouse 
117 [32,33,37,38]. C3Sn were commercially sourced (Jackson Laboratories, Bar Harbor, ME) and 
118 then bred on site. Food and water were provided ad libitum throughout the study.
119
120 Experiment 1. Effect of melatonin on 4t1 cells in vitro. To test whether melatonin treatment 
121 affects 4t1 cells in vitro we designed a custom gene expression assay, then tested how a 
122 physiologically relevant concentration of melatonin affected gene expression. 
123
124 Reliable measurements of in vivo plasma melatonin in C3H background mice show a circadian 
125 rhythm with low levels during the day of ≤ 5 pg/mL and a 6 to 8 hour elevation at night of ~25 
126 pg/mL [33]. Our test concentration of no treatment and ~25 pg/mL was intended to represent 
127 the maximal physiological range of plasma melatonin concentration.
128
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 16, 2020. ; https://doi.org/10.1101/2020.12.16.423028doi: bioRxiv preprint 
129 Our goal with gene expression assessment was to reliably identify effects of melatonin on tumor 
130 status and to probe mechanisms of melatonin effect. Gene expression is an effective tool in 
131 prognosis prediction for human breast cancer. To more directly relate our data to modern 
132 practice in human cancer assessment, we included mouse homologs of the panel of targets 
133 used on the Prosigna® PAM-50 test [30,31]. Critically, all fifty targets have a homolog in the 
134 mouse. To that panel, we added known and plausible mediators of melatonin effects on 
135 oncogenic status and transcripts associated with tumor initiation, development, and metastasis 
136 to specific tissues (Supplementary materials S1).
137
138 We first tested whether melatonin treatment would affect the number of viable cells available for 
139 mRNA extraction. Cells were grown as described above, treated with melatonin, then assayed 
140 in a standard MTT assay: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
141 (ThermoFisher, Waltham, MA) [39]. MTT is a colorimetric assay designed to test the metabolic 
142 activity of a culture. To prepare these assays, melatonin was dissolved in Dimethyl sulfoxide 
143 (DMSO) at a concentration of 1 mg/ml. The cells were plated at 4,000 cell/well in a 96-well 
144 microtiter plate and treated at concentrations ranging from 200 pg/ml down to ~0.5 pg/ml. The 
145 cells were incubated for 48 h in 200 μl of RPMI media with 1% Pen/Strep and 10% FBS. Twenty 
146 percent v/v of MTT reagent in 1X PBS (5 mg/mL) was added to each well and incubated further 
147 for 2 h. Media was removed and replaced by 100 μl of DMSO. Absorbance at 595 nm was 
148 measured using a Thermomax Molecular Device plate reader. The experiments were performed 
149 in quadruplicate. A 0.1% DMSO was used as a vehicle control and 10 μM phenyl arsine oxide 
150 (PAO) was used as a positive killing control. Statistical analysis was limited to the dose 
151 response data for melatonin treated groups with Not Treated control assumed to be 0.0 pg/ml; 
152 assessment was by Welch’s ANOVA in Prism (GraphPad, San Diego, CA).
153
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154 Then to determine how melatonin affects gene expression in 4t1 cells, we applied melatonin to 
155 cells in vitro, isolated RNA, and assessed expression of a custom panel of target genes.Cells 
156 were grown to confluence. Melatonin was added to the media in flasks at 25.0 pg/mL (N = 6 
157 flasks) with no treatment controls (N = 6). After 4 hours, a sample of media was frozen for 
158 melatonin content quantification, then cells were dissociated using trypsin, stabilized in 
159 RNAprotect cell reagent (Qiagen, Germantown, MD) and frozen for later mRNA isolation.
160
161 For control tissue, 16-week old virgin female C3Sn mice were euthanized by anesthetic 
162 overdose (200 mg/kg Ketamine, 20 mg/kg Xylazine) at the circadian phase of peak melatonin 
163 production (6 to 9 hours after lights off) under far red light (720 nm). Blood was drawn and 
164 serum isolated for melatonin quantification, protecting melatonin content by minimizing 
165 exposure of the sample to light, and by storing at -80 °C after serum separation. The thoracic 
166 and abdominal lobes of the right breast were pooled and snap frozen for RNA isolation. 
167
168 RNA was isolated using an RNAeasy Protect Cell Mini Kit (Qiagen) for in vitro cell samples, and 
169 an RNAeasy Mini Kit (Qiagen) for C3Sn mouse normal mammary tissue. All samples were 
170 reverse transcribed using an RT2 First Strand kit (Qiagen). Our panel of 88 target genes was 
171 prepared on a 96-well plate format with housekeeping genes and controls (RT2 PCR array, 
172 Qiagen). Expression was quantified on an ABI7500 real-time PCR machine (Applied 
173 Biosystems, Beverly, MA) using RT2 SYBR Green ROX qPCR mastermix (Qiagen). One non-
174 treated sample was excluded for failing quality controls.
175
176 Gene expression data for the PAM50 panel genes was used to generate a breast cancer Risk of 
177 Recurrence (ROR) prognosis score [30]. The “rorS” algorithm in genefu version 2.23.0 
178 01/31/2020 was applied [40]. The derived score is on a scale of 0–100: a low score (<40) 
179 indicates a 10-year ROR less than 10%, an intermediate score (40 to 60) indicates a 10-year 
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180 ROR of 10–20%, and a high score (>60) indicates a 10-year ROR of >20%. Comparison of 
181 ROR scores in not-treated controls and cells treated with 25pg/ml of melatonin was by unpaired 
182 parametric 2-tailed t-test in Prism (GraphPad).
183
184 Then, data was normalized by CT of Symplakin (Sympk), which had the most consistent 
185 expression across samples (Mean CT 25.5 SD 0.7), and has been identified as an optimal 
186 housekeeping gene for breast cancer gene expression [41]. Percent change was calculated 
187 relative to mean expression in ‘not treated’ controls using a power of 2. Statistical significance of 
188 change in gene expression was determined by a two-sample equal variance two-way t-test.
189
190 Experiment 2. Orthotopic allograft of 4t1 cells in C3Sn mice. A preliminary study of orthotopic 
191 allograft was conducted to demonstrate that BALB/c 4t1 cells could form viable tumor cell 
192 colonies in our melatonin competent C3Sn strain host [12]. This small sample size experiment 
193 also provided a preliminary assessment of whether pineal melatonin affected the formation of 
194 primary tumors and metastasis from those primary tumors. 
195
196 Pineal surgery. Between 7 -10 weeks of age, C3Sn mice were surgically pinealectomized 
197 (PinealX) or were sham operated leaving the pineal gland intact (Intact-control) [34]. To prevent 
198 selection and treatment bias, we evenly and randomly assigned animals in a litter to pinealX or 
199 sham surgery, then housed those animals together irrespective of their pineal status and 
200 masked experimenters to pineal status. Analgesia and anesthesia protocols included 100 mg/kg 
201 Ketamine; 10 mg/kg Xylazine; 2.5 mg/kg Acepromazine; Buprenorphine HCL at 0.1 mg/kg; and 
202 post-surgical access to an oral tablet containing 2mg of the NSAID, carprofen (Bio-Serv, 
203 Flemington, NJ). After surgical site preparation, mice were placed on a heat mat and mounted 
204 into a stereotaxic frame (Kent Scientific, Torrington, CT). A 1.5 cm midline vertical incision and 
205 blunt dissection was used to expose the scalp. A section of skull, centered on the intersection of 
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206 the sagittal and occipital fissures of the calvarium was removed using a hand drill and 2.3 mm⌀ 
207 trephine drill bit (Fine Science Tools, Foster City, CA). This approach removes the tip of the 
208 pineal gland with the cap of skull that is removed but should leave part of the pineal intact. 
209 Removal of the pineal gland was confirmed using a SZ-745 dissecting microscope (McBain, 
210 Westlake Village, CA), and the incision closed with non-absorbable 5-0 sutures (Ethicon, San 
211 Angelo, TX).
212
213 Allograft. After 2 weeks of surgical recovery, mice had an allograft of 4t1 cells to the fat pad of 
214 the left 4th mammary gland using a previously described approach [42]. Cells and mice were 
215 prepared in parallel to minimize time between cell preparation and allograft (N for each group = 
216 8, 4 male and 4 virgin female). 4t1 cells were dissociated with trypsin in RPMI media, then 
217 suspended in RPMI at a concentration of 4*107 cells/ml. Within 60 minutes, the 4t1 cell 
218 preparation was injected orthotopically to the 4th left mammary fat pad of mice. Mice were 
219 lightly anesthetized with 50 mg/kg Ketamine; 5 mg/kg Xylazine; 1.25 mg/kg acepromazine. The 
220 surgical site was prepared and a small incision made approximately 1.5 mm above the 4th 
221 nipple. 50 µl of 4T1 cells totaling 2*106 cells was then injected into the fat pad using a gas-tight 
222 micro-syringe (Hamilton, Reno, NV). Because the incision was small and shallow, no suture was 
223 used to close it. 
224
225 Tumor development and assessment. After recovery from allograft anesthesia, mice were 
226 housed in environment control cabinets under a daily cycle of 12-hours light (20 μWcm-2), and 
227 12-hours dark. At 16 weeks post cell injection, the mice were euthanized by anesthetic 
228 overdose followed by cervical dislocation. Hair was removed from the abdomen of the mouse 
229 using depilatory cream (Nair, Ewing, NJ). Left and right mammary chains and the lungs of each 
230 animal were collected and fixed in 4% paraformaldehyde (PFA) (Sigma-Aldrich, St. Louis, MO) 
231 for 6 hours, then transferred to 1% phosphate buffered saline (PBS) and stored at 4 °C. Tissue 
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232 was embedded in Tissue Freezing Medium (General Data, Cincinnati, OH) sectioned at 10-16 
233 μm on a Shandon FE Cryostat (Thermo Fisher scientific, Waltham, MA). Slides were stained 
234 with Hematoxylin and Eosin (all reagents from VWR, Radnor, PA). Number of sections was 
235 recorded to allow size calculation. Images were recorded on a Leica ICC50 HD and processed 
236 with Microsoft Image Composite Editor.
237
238 Larger tumors were defined as a cluster of dense cells with a defined border demarcating it from 
239 surrounding normal adipose tissue. We assumed a solid tumor was a single mass unless there 
240 were three sequential sections with no tumor between two masses. After assessments, animal 
241 pineal status was unmasked and total tumor load compared between experimental PinealX and 
242 Intact-control groups using Welch’s t-test.
243
244 Single epithelial cells in the fat mass of the mammary pad might be invasive 4t1 cells. To 
245 assess differences in this potential marker of local invasiveness, we quantified the extent of 
246 triple negative tumor presence in the left breast away from the introduction site at the abdominal 
247 or 4th mammary gland using a percentage-based severity grade. Invasiveness was defined as a 
248 small dense cluster of cells that displayed branching into surrounding tissue. The invasive 
249 burden was measured by counting invasive clusters of cells in a section (0-7, 7 being the most 
250 severe). Because this scoring approach is subjective, scorers were masked to animal ID and 
251 analysis by three separate scorers was averaged. After assessments, animal pineal status was 
252 unmasked and total tumor load compared between experimental PinealX and Intact-control 
253 groups using Welch’s t-test.
254
255 Experiment 3. Effects of pineal melatonin on metastasis of 4t1 cells from tail-vein allograft. It has 
256 been demonstrated that tail-vein injection allograft of 4t1 cells establishes metastases [36]. We 
257 therefore adopted this model to determine whether melatonin affects the extent and sites of 
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258 metastases of 4t1 TNBC cells. We focused on common metastatic sites for breast cancer: 
259 breast, liver, and lymph nodes. However, there was potential for low levels of metastatic burden 
260 in these tissues, so we developed a gDNA based quantification host and donor content in 
261 tissues using strain selective qPCR (see supplementary material S2). This is similar to the 
262 approach used in quantifying xenografts by others [43–45].
263
264 Pineal surgery. Mice were Intact-control (n=10, 6 female and 4 male) or PinealX (n=13, 6 female 
265 and 7 male) operated between 7 and 10 weeks old as described for experiment 3. 
266
267 Tail-vein injection. After 2 weeks of surgical recovery, mice had an allograft of 4t1 cells to the 
268 tail-vein using a previously described approach [27,36]. Cells and mice were prepared in parallel 
269 to minimize time between cell preparation and allograft. 4t1 cells were dissociated with trypsin in 
270 RPMI media, then suspended in RPMI at a concentration of 5*107 cells/ml. Within 60 minutes, 
271 0.1 ml (500,000 cells) were injected into the tail vein of mice lightly anesthetized with 50 mg/kg 
272 Ketamine; 5 mg/kg Xylazine; 1.25 mg/kg acepromazine. After cell injection, mice were housed 
273 in a light tight environment control cabinet with a 12-hour light, 12-hour dark daily cycle. 
274
275 Tissue collection. At 14 days post allograft, mice were euthanized by anesthetic overdose (200 
276 mg/kg Ketamine, 20 mg/kg Xylazine) at the circadian phase of peak melatonin production (6 to 
277 9 hours after lights off) under far red light (720 nm). Blood was drawn and serum isolated for 
278 melatonin quantification, protecting melatonin content by minimizing exposure of the sample to 
279 light, and by storing at -80 °C after serum separation. Tissue samples of common metastatic 
280 sites were then collected into dry tubes for snap-freezing.  Each lobe of the lung was collected 
281 separately: right cranial, middle, caudal, accessory and left lung. Both inguinal lymph nodes 
282 were pooled. The thoracic and abdominal sections of the right breast were pooled. Liver 
283 collection was limited to a ventral biopsy. 
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284
285 Melatonin status confirmation. A direct melatonin immunoassay was used to measure melatonin 
286 concentration in serum at the time cells were harvested (MEL31-K01 direct melatonin 
287 serum/plasma EIA kit, Eagle Biosciences, Nashua, NH). Samples were tested according to 
288 manufacturer guidelines and absorbance at 450nm measured on an Infinite MPlex 96-well plate 
289 reader (Tecan, Baldwin Park, CA). A standard curve was plotted using a 4-parameter sigmoid 
290 function, and concentrations interpolated from the curve, in Prism (GraphPad).
291
292 DNA isolation. DNA was isolated using a DNeasy Blood and Tissue kit (Qiagen). After adding a 
293 lysis buffer, tissue was mechanically disrupted using a Tissueruptor II with disposable probes 
294 (Qiagen). Further lysis was promoted with Proteinase K step for 2 hours before finishing DNA 
295 isolation. The exception to this protocol was for bone, where the Proteinase K step was 40 
296 hours, and then mechanical disruption was completed with a Tissueruptor II. Quality of DNA 
297 was tested by 260/280nm or 260/230nm ratios on a Nanodrop spectrophotometer (Thermo 
298 Fisher). Quantity of DNA was measured by the 260nm adjusted absorbance. 
299
300 gDNA quantification. Isolated gDNA was amplified in triplicate with strain-selective BALB/c and 
301 C3H primers (IDT, Coralville, IA) and a qPCR and Go SYBR® Hi-ROX Kit (MP Biomedicals, 
302 Irvine, CA) on an ABI7500 real-time PCR machine (Applied Biosystems). Threshold cycle (CT) 
303 values were converted to percent of total gDNA using a power of 2. After assessment, animal 
304 pineal status was unmasked and total tumor load compared between Intact-control and PinealX 
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310 Experiment 1. Effect of melatonin on 4t1 cells in vitro. There were viable 4t1 cells under all 
311 concentrations of melatonin treatment, so we were able to select a concentration of 
312 melatonin for testing gene expression that was a maximal physiological concentration 
313 (Figure 1). Melatonin had no identifiable effects on the gross morphology of 4t1 cells. In 
314 addition, there was no effect on proliferation/survival of 4t1 cells in an MTT assay (Welch’s 
315 ANOVA of melatonin treatment dose response curve P = 0.29; W 1.4, DFn 9.0, DFd 11.3). 
316 Comparison of no treatment control confirmed that there was no difference to DMSO vehicle 
317 control (Mann Whitney test P = 0.20), and that cells were effectively killed by PAO positive 
318 control. 
319
320 Figure 1. Effects of melatonin on 4t1 cell morphology and viability. (A) An example image 
321 of 4t1 cells with melatonin treatment at a concentration much higher than physiological levels. 
322 (B) In the MTT assay, viable cells breakdown of tetrazolium dye to formazan, which has 
323 absorbance at 595nm, so absorbance = metabolic activity = viable cells. Absorbance for 4t1 
324 cells is shown with melatonin treatment at a range of concentrations. Melatonin concentration 
325 gradient is implied by shading of bars on the graph. PAO positive killing control and DMSO 
326 vehicle control are also shown. Data are expressed as mean ± SEM.    
327
328 Gene expression confirmed the TNBC status of 4t1 cells, with significantly reduced expression 
329 of Pgr (<0.01% of normal breast expression, P< 0.00001), Esr1 (1.2% of normal breast, P< 
330 0.00001), and Errb2/Her2 (10.4% of normal breast, P< 0.0001) (Figure 2A, Table S1). These 
331 data also identified significantly lower expression of melatonin receptor Mtnr1a (3.0% of normal 
332 breast, P< 0.001), and the melatonin receptor regulated transcription factor Rora (0.05% of 
333 normal breast, P< 0.00001).
334
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335 Figure 2. Gene expression of 4t1 cells in vitro. Expression of selected genes was determined 
336 by qPCR for 4t1 cells grown in cell culture media.  (A) Esr1, Pgr and Errb2/Her2 are the 
337 hormone receptors used to identify breast cancer as triple negative. Gene expression is shown 
338 as percentage of the expression in normal mammary tissue from C3Sn mice, after normalizing 
339 samples to a housekeeping control Symplekin, with bars showing Mean and SEM. (B) 
340 Expression levels of the PAM50 panel of genes allowed a Risk-Of-Recurrence score (ROR) to 
341 be calculated for experimental replicates of 4t1 cells grown in untreated cell culture media (NT) 
342 and in media treated with 25pg/ml of melatonin for 4-hours, which approximates peak plasma 
343 melatonin in mice. (C) Melatonin treatment significantly changed gene expression of multiple 
344 targets in our assay. Shading shows genes that are part of the PAM50 panel, non-shaded 
345 genes were our melatonin mechanism focused additions to the panel. Mean and SEM percent 
346 change was calculated against expression in cells with no melatonin pretreatment.  Significance 
347 in all panels is indicated by * P<0.05, ** P<0.01, and *** P<0.001.
348
349 There was an effect of melatonin treatment within the physiological range (25pg/ml) on gene 
350 expression of 4t1 cells in culture (Figure 2B). Assessment of the genes that constitute the 
351 PAM50 human breast cancer Risk-Of-Recurrence (ROR) prognosis score calculator identified a 
352 significant decrease in oncostatic status with melatonin treatment (P = 0.008; F = 1.61). Non-
353 treated cells had a high ROR score (Mean 65.5 ± 10.6 SEM), which in human patients identifies 
354 10-year ROR as greater than 20%. Cells treated with 25pg/ml of melatonin had a low score 
355 (Mean 20.8 ± 8.3 SEM), which in human patients identifies 10-year ROR as less than 10%. 
356
357 Among the PAM50 panel and our added targets, fifteen genes showed a significant increase in 
358 expression with melatonin pretreatment (Figure 2C). These included genes that: anchor cells 
359 into tissue (Cdh2, Nrp1 and Sema3f), enable invasion and metastasis (Krt14, Mlph, Mmp1a, 
360 Mmp2, Mmp11, St6galnac5), and that affect the rate of differentiation, proliferation and/or 
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361 apoptosis (Mapt, Mdm2, Mybl2, Myc, Nanog, Tfap2c). Note: when identifying changes caused 
362 by melatonin treatment, we did not correct for multiple measures. This approach is likely to 
363 include type 1 errors (false positives), but with Bonferroni correction, type 2 errors are likely 
364 (false negatives), and due to the large number of targets in our panel, with correction none of 
365 the changes were significant.
366
367 Experiment 2. Effect of pineal melatonin on a 4t1 cell orthotopic allograft into C3Sn mice. 
368 Orthotopic allograft was intended to test whether 4t1 cells were viable in a C3Sn mouse, and to 
369 allow us to assess whether pineal melatonin had any effect on 4t1 tumor burden, invasiveness 
370 and metastasis from an orthotopic placement.
371
372 A tumor cell burden was present in the majority of mice, demonstrating that 4t1 tumors will 
373 establish themselves successfully in a C3Sn host mouse, regardless of sex or pineal/melatonin 
374 status (Figure 3). There was a non-significant increase in the incidence of solid tumors in 
375 female PinealX mice (P = 0.38, F = 8.0). There were also single epithelial cells in the fat mass of 
376 the mammary pad that might be invasive 4t1 cells. If these are invasive 4t1 cells, there was no 
377 difference in the severity of local invasion between female PinealX and Intact-control (P = 0.68, 
378 F = 15.5). 
379
380 Figure 3.  Effect of pineal melatonin on orthotopic allograft viability. (A) Example of a solid 
381 tumor at the allograft site in the lower left breast chain. (B) Example of single epithelial cells in 
382 mammary fat pad that might be invasive 4t1 cells. (C) The number of solid tumors in the lower 
383 left mammary chain of Intact-Pineal control and PinealX mice is expressed as Mean ± SEM. 
384 Tumor numbers are shown for female mice, male mice, and combined groups of male and 
385 female mice. 
386
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387 Experiment 3. Effect of melatonin on metastasis of 4t1 cells from tail-vein allograft. There was 
388 no effect of pineal status on metastases to lung, breast, lymph or liver (Figure 4). Pineal surgery 
389 significantly reduced serum melatonin (Mean ± SD serum melatonin pg/ml: Intact-Control 
390 32.2pg/ml ± 4.7; PinealX 16.2 ± 2.1; P < 0.0001; F = 5.11). There was no sex difference in mid-
391 dark-phase serum melatonin (Intact-Control Male 31.0 ± 5.8; Intact-Control Female 33.5 ± 4.0; 
392 P = 0.40).
393
394 Figure 4. Effect of pineal status on metastasis. 4t1 cell burden is shown as a percentage of 
395 the total tissue calculated by strain specific qPCR: 4t1 cells have a BALB/c origin so the 
396 proportion of BALB/c and C3Sn host gDNA provided a measure of 4t1 cell content. Mean and 
397 SEM of data are shown for Intact-Control and PinealX mice for: (A) breast, (B) lung, (C) lymph, 
398 and (D) liver. Comparison is Intact-Control versus PinealX for male mice, female mice, and then 
399 combined male and female data.
400
401 However, there was a significant difference in metastases of 4t1 cells to the breast of male and 
402 female mice (Mean and SD females = 16.2 ± 4.6, males = 10.4 ± 3.0, P = 0.002; two-tailed, 
403 equal variance t-test, significance threshold Bonferroni corrected for multiple measures from 
404 0.05 to 0.0127) (Figure 5). There was also no effect of sex on metastases to lung, lymph or 
405 liver.
406
407 Figure 5. Effect of sex on metastasis. 4t1 cell burden is shown as a percentage of the total 
408 tissue calculated by strain specific qPCR. Mean and SD of data separated by sex are shown for: 
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413 There is compelling evidence that reduced melatonin signaling correlates with increased 
414 incidence and poor prognosis in TNBC patients [5,9,22,24,25,29]. However, studies of 
415 melatonin effects on TNBC have typically been limited to very high, non-physiological doses of 
416 melatonin, and/or used strains of mice that do not make endogenous melatonin so are chronic 
417 deficits in melatonin with unspecified developmental consequences of that deficit. The goal of 
418 this study was to determine whether the relatively small reductions in pineal melatonin that 
419 might occur with use of artificial light-at-night (ALAN), have any effect on a hormone receptor 
420 deficient breast cancer.
421
422 Assessment of the effect of melatonin on 4t1 cells in vitro was intended to identify any effect on 
423 tumor cell status (ROR score) and suggest mechanisms mediating effects of melatonin. The 
424 lack of melatonin effect on survival of 4t1 cells in vitro, was consistent with one study of MDA-
425 MB-231 and HCC-70 TNBC cells, but different from a later study of MDA-MB-231 cells [22,23]. 
426 However, there was a clear effect of melatonin on gene expression. Gene expression also 
427 confirmed that 4t1 cells are valid as a model of TNBC: Pgr was undetectable, and Esr1 and 
428 Errb2/Her2 were considerably reduced. This is consistent with the finding that 4t1 cells lack 
429 Esr1 protein and an estradiol growth response [27]. However, this is different from the observed 
430 expression of Esr1 and Errb2 in another recent study, which likely reflects our use of C3Sn 
431 mouse to provide normal breast gene expression data [29].
432
433 Notably, the significant reduction in PAM50 ROR prognosis score with melatonin treatment 
434 suggested that melatonin has the potential to dramatically reduce the aggressiveness of 4t1 
435 TNBC [30,31]. The caveat with the ROR observation is that the PAM50 panel and ROR 
436 prognosis score are developed and clinically validated for assessment of human breast cancer. 
437 However, we felt this panel would make both typing and prognosis assessment more 
438 translationally relevant in this and future studies. For example, the PAM50 panel was developed 
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439 for a variety of breast cancer types (Luminal A, Luminal B, HER2-enriched, basal-like and 
440 normal-like), and tools to derive the clinically validated prognosis score as a 10-year risk of 
441 recurrence (ROR) are freely available [40].
442
443 Of the melatonin induced changes in specific genes, patterns of interest included an increase in 
444 genes associated with tissue remodeling (Mmp1a, Mmp2, Mmp11), but also an increase in cell-
445 cell anchoring genes (Cdh2, Sema3f, Nrp1). The sum of these changes may be negative, 
446 positive or neutral, which emphasizes the value of a clinically validated prognosis predictor such 
447 as the PAM50 ROR. 
448
449 Given the effect of gene expression, the limited effect of deficits in melatonin in vivo, was 
450 unexpected. We had successfully developed a surgical model of partial pineal gland removal 
451 that reduces plasma melatonin by ~50%. In our preliminary study to test allograft viability, we 
452 saw a non-significant increase in burden of solid tumors in female mice from 4t1 cells introduced 
453 orthotopically. However, in a larger cohort with 4t1 cells introduced by tail-vein injection, we saw 
454 no effect of pineal status on metastasis. Interestingly, the burden of 4t1 cells from tail-vein 
455 allograft was significantly higher in the breast of female mice. This measurement was 
456 proportional to total mammary tissue collected so could result from a sex-hormone effect on 4t1 
457 cells or a functional difference in the mammary tissue of virgin female mice [46].
458
459 While we saw no effect of pineal melatonin on metastasis, our approach of quantifying 
460 metastases by gDNA was successful. Metastases of 4t1 cells from tail vein injection form 
461 disseminated colonies, which would make quantification difficult [36]. Others have developed 
462 methods for quantification of submicroscopic xenograft metastases using DNA quantification 
463 [45]. The genetic differences between BALB/c 4t1 cells and our C3Sn host allowed us to design 
464 strain specific qPCR primers, which allowed us to quantify dispersed metastases from a 
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465 transplant to a member of the same species [47]. To our knowledge, this approach has not been 
466 applied to an allograft. 
467
468 Our gene expression data suggests that melatonin does have a meaningful effect on TNBC. 
469 The lack of melatonin effect in an MTT assay and on metastasis from tail-vein injection, 
470 suggests the effect is not on proliferation or invasion of tissues from the vasculature. In that 
471 context, the trend for increased tumor burden from orthotopic allograft in females with deficits in 
472 pineal melatonin could suggest any protective effects occur earlier in stages of neoplastic 
473 development. For example, the increased expression of Cdh2, Sema3f and Nrp1 would reduce 
474 shedding of cells from a tumor. This indicates a need to more extensively study in vitro 
475 properties (colony formation, wound healing, and trans-well cell invasion) and the time course of 
476 orthotopic allograft tumor development and metastasis, as well as incidence of TNBC induced 
477 by chemical carcinogens in our model.
478
479 Clinical relevance. Exposure to LAN will reduce the duration and/or amount of melatonin action. 
480 Currently our data finds no in vivo effect of melatonin deficits, but in vitro gene expression does 
481 suggest melatonin could affect TNBC pathogenesis. If melatonin acts earlier in oncogenesis 
482 than invasion of circulating cells into tissue, such as reducing the prior shedding of cells from a 
483 tumor, then effective risk reduction would be best achieved with prophylactic reductions in ALAN 
484 exposure or use of melatonin supplements or agonists. Even if the risk reduction is modest, the 
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